EHA 2015: Expert opinions on new treatment standard in multiple myeloma
EHA 2015: Expert opinions on new treatment standard in multiple myeloma
Exploring "bad luck" - why do some patients develop myeloid leukaemia?
The latest in multiple myeloma: a European and US perspective
Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid leukaemia
Advances in the treatment and management of CLL
Transplantation combined with novel agents optimal treatment for multiple myeloma
Monoclonal antibodies and multiple myeloma
New definition for multiple myeloma improves patient outcomes
Factors influencing response to blinatumomab in relapsed/refractory ALL
Evidence for kinase inhibitor activity in acute myeloid leukaemia
Targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia
New targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia